Figure 2.

Antileukemia activity of invadosome-targeting peptides in OCI-AML3 xenografts. (A) Shown are representatives of peptide-treated leukemia-bearing mice 20 days after OCI-AML-3 cell inoculation. (B and C) Tumor sizes of OCI-AML-3–derived xenografts. Bars represent means from each peptide group. *Student t test, P < .001 of either HFDDDE- or DDGW-treated mice compared with control mice. No significant differences were detected between DFEDHD vs the saline group (t test, P = .107) or KKGW vs the saline group (t test, P = .65). Mice were killed when leukemia-derived xenograft volume reached 700 mm³ as indicated. (D-E) Kaplan-Meier actuarial survival analysis of the cohorts is shown. Differences were statistically significant at P < .001 and P = .004 for HFDDDE-treated group (D, dashed line) and DDGW-treated group (E, dashed line), respectively, compared with control DFEDHD-treated mice (D, solid line) or KKGW peptide-treated group (E, solid line).